Apr 05, 2022 8:30am EDT Processa Pharmaceuticals Announces First Patient Enrolled in the PCS12852 Phase 2A Trial for the Treatment of Gastroparesis
Mar 30, 2022 4:00pm EDT Processa Pharmaceuticals Announces Year-End 2021 Results and Provides Corporate Update
Mar 23, 2022 8:30am EDT Processa Pharmaceuticals To Host Conference Call to Discuss Fourth Quarter 2021 Results and Provide Drug Development Update on March 30 at 4:30 p.m. EST
Mar 10, 2022 8:30am EST Processa Pharmaceuticals CEO Dr. David Young To Present at the Oppenheimer 32nd Annual Healthcare Conference
Jan 26, 2022 8:15am EST Processa Pharmaceuticals CEO Dr. David Young Issues Letter to Shareholders Providing Outlook for 2022
Nov 11, 2021 4:05pm EST Processa Pharmaceuticals Announces Third Quarter 2021 Results and Provides Corporate Update
Nov 04, 2021 8:15am EDT Processa Pharmaceuticals Announces Next Generation Capecitabine (Combination of PCS6422 and Capecitabine) Inhibits DPD in Phase 1b Interim Analysis
Oct 26, 2021 8:30am EDT Processa Pharmaceuticals Schedules Conference Call to Discuss Third Quarter Results and Provide Drug Development Update on November 11 at 5:30 p.m. EST
Oct 12, 2021 8:30am EDT Processa Pharmaceuticals Cleared by FDA to Proceed with Phase 2a Trial for the Treatment of Gastroparesis
Sep 16, 2021 11:05am EDT Processa Pharmaceuticals to Participate in Upcoming Investor Conferences - Update
